Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a multicenter, placebo-controlled and randomized Phase 2 clinical trial to evaluate Triplex, a cytomegalovirus, CMV, vaccine, when administered to human leukocyte antigen, HLA, matched related stem cell donors to reduce CMV events in patients undergoing hematopoietic stem cell transplantation, HSCT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO: